Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study

Introduction: Atezolizumab + bevacizumab showed survival benefit in patients with unresectable hepatocellular carcinoma (HCC) vs sorafenib in the Phase III IMbrave150 study. This exploratory analysis examined the prognostic impact of baseline albumin-bilirubin (ALBI) score. Methods: Patients with t...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Masatoshi Kudo, Richard S. Finn, Ann-Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Karger Publishers 2023-03-01
coleção:	Liver Cancer
Acesso em linha:	https://www.karger.com/Article/FullText/529996
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!